InvestorLens

REGN — REGENERON PHARMACEUTICALS

Health Care · Biotechnology

Sign in to save7 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying REGN?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 2 selling last quarter
14
Macro Tailwind
Macro conditions are mixed for this sector
55
Congressional Activity
1 congressional purchase, 1 sale disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their REGN position last quarter, 0 bought and 2 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime). 1 congressional purchase, 1 sale disclosed in the last 6 months.

Supporting evidence
  • +7 tracked investors reported holding REGN at their latest filing
  • +Macro Health is 52/100 in a Squeeze regime — historically acceptable for Health Caresource
Contradicting evidence — always shown
  • −2 tracked investors reduced or exited last quarter (1 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About REGENERON PHARMACEUTICALS (REGN)

REGENERON PHARMACEUTICALS (REGN) appears in the most recent 13F filings of 7 tracked institutional investors. REGENERON PHARMACEUTICALS is classified in the Health Care sector (Biotechnology industry). The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $343M. Across recent filings, tracked investors recorded 3 new positions, 0 increased, 3 reduced, and 2 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in REGN

38
/100
Institutional Distribution
Added / Increased3
Reduced3
Exited2
BearishBullish
Crowded Trade Score™

How many top investors track REGN

47
/100
Moderate Interest
7investors

Several tracked investors have exposure.

UndiscoveredCrowded
151015+

REGN Ownership Composition

How REGENERON PHARMACEUTICALS is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
67% of tracked value
Institutions
7
tracked investors
Total Reported
$684.6M
combined 13F value
Sectors3
  • Other66.5%
  • Hedge Funds33.5%
  • Growth Funds0.0%
Other(4)
66.5%
Hedge Funds(2)
33.5%
Growth Funds(1)
0.0%

Tracked investors reporting REGN

  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    132.2K
    Value
    $102.2M
    % Portfolio
    0.04%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    433.8K
    Value
    $335.2M
    % Portfolio
    0.05%
  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    150.6K
    Value
    $116.3M
    % Portfolio
    0.15%
  • Michael BurryJun 30, 2025
    Scion Asset Management
    Shares
    215K
    Value
    $112.9M
    % Portfolio
    19.52%
  • Paul Tudor JonesMar 31, 2026
    Tudor Investment Corp
    Shares
    700
    Value
    $540.8K
    % Portfolio
    0.00%
  • Ray DalioMar 31, 2026
    Bridgewater Associates
    Shares
    22.7K
    Value
    $17.6M
    % Portfolio
    0.08%
  • Cathie WoodDec 31, 2025
    ARK Investment Management
    Shares
    110
    Value
    $84
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold REGN?
7 tracked institutional investors disclosed a position in REGN (REGENERON PHARMACEUTICALS) in their most recent 13F filing.
Who is the largest institutional holder of REGN?
Izzy Englander, Millennium Management, holds the largest disclosed position in REGN, valued at $343M.
Did institutional ownership of REGN increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 0 increased, 3 reduced, and 2 fully exited REGN.
What sector is REGN in?
REGENERON PHARMACEUTICALS is classified in the Health Care GICS sector, Biotechnology industry.
Where does this REGN ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.